Efficacy and safety of gefapixant, a P2X3 receptor antagonist, in refractory chronic cough and unexplained chronic cough (COUGH-1 and COUGH-2): results from two double-blind, randomised, parallel-group, placebo-controlled, phase 3 trials
Queen's University Belfast · King's College London · +7 more institutions
Indexed incrossrefpubmed
Abstract
No abstract available for this paper.
Citation impact
303
total citations
- FWCI
- 42.46
- Percentile
- 100%
- References
- 44
Citations per year
Authors
14Topics & keywords
Topics
Keywords
- Chronic cough
- Medicine
- Placebo
- Refractory (planetary science)
- Double blind
- Anesthesia
- Antagonist
- Randomized controlled trial
UN Sustainable Development Goals
- Good health and well-being
No related works found for this paper.